AYTU BIOPHARMA, INC (AYTU): debt financing — Aytu expands debt facility to $13M term loan plus $1.5M revolver; maturity extended to June 2029 for EXXUA launch

AYTU BIOPHARMA, INC

Term loan principal increased to $13.0M from $11.1M; maturity extended to June 12, 2029.
Revolving credit facility expanded by $1.5M incremental advance at SOFR+5.5%, repayable $125K/month starting August 1, 2025.
Provides working capital flexibility as Aytu prepares for commercial launch of EXXUA (gepirone) for MDD expected Q4 2025.
Follows earlier $16.6M public offering closed earlier in June 2025.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

AYTU BIOPHARMA, INC amended revolving credit of $1.5 million incremental advance with Eclipse Business Capital LLC at SOFR plus 5.50% maturing June 12, 2029.

Instrument: revolving credit
Principal: $1.5 million incremental advance
Counterparty: Eclipse Business Capital LLC
Rate: SOFR plus 5.50%
Maturity: June 12, 2029
Event: amendment

Exact text from the filing

extended the revolving credit facility (the “Eclipse Revolving Loan”) maturity date to June 12, 2029, and increased the potential maximum borrowing base pursuant to a $1.5 million incremental advance (the “Eclipse Incremental Advance”), at an interest rate of the SOFR plus 5.50%

View on SEC.gov

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

AYTU BIOPHARMA, INC amended term loan of outstanding principal amount of $13.0 million with Eclipse Business Capital LLC maturing June 12, 2029.

Instrument: term loan
Principal: outstanding principal amount of $13.0 million
Counterparty: Eclipse Business Capital LLC
Maturity: June 12, 2029
Event: amendment

Exact text from the filing

extended the term loan (the “Eclipse Term Loan”) maturity date to June 12, 2029, and increased the Eclipse Term Loan resulting in an outstanding principal amount of $13.0 million on the closing date of the Eclipse Amendment

View on SEC.gov

Browse all debt financings →

AYTU BIOPHARMA, INC filing history →

Source: SEC EDGAR

accession 0001437749-25-020973

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.